Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16.
iScience. 2022.
PMID: 36072551
Free PMC article.